CEVI CellaVision AB

CellaVision AB presents the first quarter for 2020 on April 22, at 11:00 CET

CellaVision AB presents the first quarter for 2020 on April 22, at 11:00 CET

The information was submitted to the public on April 15, 2020 at 8:20 CET

CellaVision AB (publ) will publish the Interim report for the first quarter 2020 on April 22, 2020 at 8:20 CET.

The report will be available at

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where

Zlatko Rihter, President & CEO, will present and comment the report.

The presentation will be in English via a conference call or audio webcast:

Phone number for the conference:

SE: +46 8 50 55 83 75

UK: +44 333 300 90 34

US: +1 833 526 83 95

No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time to facilitate a timely start.



About CellaVision

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 18 local market support organizations covering more than 35 countries. In 2019, sales were SEK 462 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at

Attachment

EN
15/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CellaVision AB

CellaVision AB: 1 director

A director at CellaVision AB sold 100,000 shares at 225.000SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Rickard Anderkrans ... (+3)
  • Rickard Anderkrans
  • Victor Forssell
  • Viktor Sundberg

Cellavision - Terminating coverage

ABGSC ceases coverage of Cellavision Due to a reorganisation of research priorities Last published estimates are shown in this report

 PRESS RELEASE

CellaVision AB: God lönsamhet trots negativ covid-19-effekt

CellaVision AB: God lönsamhet trots negativ covid-19-effekt Informationen lämnades för offentliggörande 2020-07-16 kl 08.20 1 april–30 juni 2020 Nettoomsättningen ökade med 5% till 118,0 MSEK (112,4).Organiskt minskade omsättningen med 15% (+18).EBITDA uppgick till 36,2 MSEK (41,3).EBITDA-marginalen uppgick till 31% (37).Resultatet före skatt uppgick till 34,4 MSEK (37,9).Resultat per aktie före och efter utspädning uppgick till 1,14 SEK (1,27).Kassaflödet från den löpande verksamheten uppgick till 34,1 MSEK (17,3). 1 januari–30 juni 2020   Nettoomsättningen ökade med 17% till 252,5 MS...

 PRESS RELEASE

CellaVision AB: Good profitability despite negative COVID-19-effect

CellaVision AB: Good profitability despite negative COVID-19-effect The information was submitted for publication at 08.20 CET on July 16, 2020 1 April -30 June 2020 Net sales increased by 5% to SEK 118.0 million (112.4).Sales decreased organically by 15% (+18).EBITDA amounted to SEK 36.2 million (41.3).EBITDA margin amounted to 31% (37).Profit before tax amounted to SEK 34.4 million (37.9).Earnings per share before and after dilution were SEK 1.14 (1.27).Cash flow from operating activities amounted to SEK 34.1 million (17.3). 1 January-30 June 2020 Net sales increased by 17% to SEK 252...

 PRESS RELEASE

CellaVision AB: Zlatko Rihter leaves his position as CEO at CellaVisio...

CellaVision AB: Zlatko Rihter leaves his position as CEO at CellaVision AB The information was released for public disclosure on May 29, 2020, at 08:20 CET CellaVision's President and CEO, Zlatko Rihter, has informed the Board of Directors that he wishes to resign as CEO of the company in order to take on the position as President and CEO of the medical technology company Mölnlycke Health Care AB. Zlatko Rihter has been CEO of CellaVision since January 1, 2015. Zlatko will continue in his current role during the notice period and leave his assignment by November 28, 2020 at the latest. Th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch